Cover Image
市場調查報告書

慢性蕁麻疹:開發中產品分析

Chronic Urticaria Or Hives - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213077
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
慢性蕁麻疹:開發中產品分析 Chronic Urticaria Or Hives - Pipeline Review, H1 2017
出版日期: 2017年05月09日 內容資訊: 英文 52 Pages
簡介

慢性蕁麻疹指的是身上時而出現時而消失的隆起,有各種大小,呈紅色或白色並發癢的腫疹。大部分情況下,蕁麻疹皆可在1週內穩定,偶而也有人會長期持續這些症狀。持續6週以上的蕁麻疹,及暫時消失但卻又頻繁複發的蕁麻疹就稱為慢性蕁麻疹。

本報告提供全球各國慢性蕁麻疹治療用之開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

慢性蕁麻疹概要

治療藥的開發

  • 開發中產品的概要

慢性蕁麻疹:企業開發中的治療藥

慢性蕁麻疹:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

慢性蕁麻疹:企業開發中的產品

慢性蕁麻疹的治療藥開發企業

  • AstraZeneca Plc
  • Biofrontera AG
  • ELORAC, Inc.
  • Faes Farma, SA
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • J Uriach Y Compania, S.A.
  • Mabtech Limited
  • Merck & Co., Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Panacea Biotec Limited

慢性蕁麻疹:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

慢性蕁麻疹:最近的開發平台趨勢

慢性蕁麻疹:暫停中的計劃

慢性蕁麻疹:開發中止的產品

慢性蕁麻疹:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9231IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 3, 3, 1 and 3 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Urticaria Or Hives - Overview
    • Chronic Urticaria Or Hives - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chronic Urticaria Or Hives - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
    • Biofrontera AG
    • ELORAC Inc
    • Faes Farma SA
    • Genentech Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • J Uriach Y Compania SA
    • Mycenax Biotech Inc
    • Novartis AG
    • Panacea Biotec Ltd
    • Synermore Biologics Co Ltd
  • Chronic Urticaria Or Hives - Drug Profiles
    • BF-Derm-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetirizine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cidoxepin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GDC-0853 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2646264 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ligelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rupatadine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
    • Featured News & Press Releases
      • Jan 25, 2017: Pediapharm Announces the Commercial Launch of Rupall (Rupatadine) in Canada
      • Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada
      • Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan
      • Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan
      • Jul 22, 2016: Uriach receives Health Canada approval for rupatadine
      • Jul 21, 2016: Pediapharm Receives Health Canada Approval for Rupatadine
      • Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN
      • Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
      • May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration
      • Jul 09, 2012: Uriach Extends Collaboration With Hyphens On Rupafin Oral Solution
      • Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico
      • Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
      • Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
      • Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
      • Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by J Uriach Y Compania SA, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Ltd, H1 2017
  • Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H1 2017
  • Chronic Urticaria Or Hives - Dormant Projects, H1 2017
  • Chronic Urticaria Or Hives - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top